Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy - Article
Clinical Trial: Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
This study is no longer recruiting patients.
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as interferon alfa-2b use different ways to stimulate the immune system and stop cancer cells from growing.
|Condition||Treatment or Intervention||Phase|
|stage II chronic lymphocytic leukemia |
stage I multiple myeloma
stage II multiple myeloma
stage IV chronic lymphocytic leukemia
stage III multiple myeloma
stage I chronic lymphocytic leukemia
stage III chronic lymphocytic leukemia
B-cell Chronic Lymphocytic Leukemia
Quality of Life
| Drug: interferon alfa |
|Phase II |
MedlinePlus related topics: Leukemia, Adult Acute; Leukemia, Adult Chronic; Leukemia, Childhood; Multiple Myeloma
Study Type: Interventional
Study Design: Treatment
Study start: June 1998
III. Compare the survival rates of these patients to similar patients treated in published studies.
IV. Determine the quality of life of these patients on these regimens.
PROTOCOL OUTLINE: Patients enter one of two treatment arms:
Quality of life is assessed monthly during therapy.
Patients are followed every 3 months for 1 year, and then annually for up to 5 years.
PROJECTED ACCRUAL: A total of 60-80 patients (30-40 per disease type) will be accrued for this study.
PROTOCOL ENTRY CRITERIA:
- B-cell chronic lymphocytic leukemia or multiple myeloma in remission that was previously treated with chemotherapy without disease progression
- See Disease Characteristics
- Age: Not specified
- Performance status: ECOG 0-2
- Life expectancy: Not specified
- Hematopoietic: Lymphocyte count less than 10,000/mm3
- Hepatic: Not specified
- Renal: Not specified
- Other: Not pregnant or nursing; Fertile patients must use effective contraception; No active infection or other concurrent lifethreatening disease; Medical condition satisfactory for treatment with chemotherapy
Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92658, United States
Baptist Regional Cancer Center - Knoxville, Knoxville, Tennessee, 37901, United States
St. Joseph Regional Cancer Center, Bryan, Texas, 77802, United States
Record last reviewed: August 2004
Last Updated: October 13, 2004
Record first received: December 10, 1999
ClinicalTrials.gov Identifier: NCT00004040
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005